UCSF Jul 7, 2022 California Passes State Budget Including $19.3M for Precision Medicine Premium May 17, 2022 Routine Genomic Profiling Could Improve Diagnosis of Aggressive Brain Cancers, Patient Outcomes Premium Apr 11, 2022 Adding Genetic Information to PSA Improves Biomarker's Performance in Prostate Cancer Diagnosis May 28, 2021 In Brief This Week: Legend Biotech, Center for Genomic Interpretation, Prostate Cancer Foundation Apr 20, 2021 Prostate Cancer Study Shows Oncotype DX GPS Test Accurately Measures Long-Term Outcomes Premium Mar 23, 2021 Caris-Led Team Searches for Clues to Poor COVID-19 Outcomes in Cancer Patients' Transcriptome Data Premium Feb 9, 2021 Germline Genetic Variants May Influence Tumor Immune Microenvironment, Treatment Response Dec 4, 2020 Breast Cancer Trial Data Supports Neoadjuvant Use of Natera Liquid Biopsy Premium Aug 7, 2020 UCSF Glioblastoma Projects Using Molecular Data to Inform Subtypes, Match Patients to Treatments Premium Apr 3, 2020 Breast Cancer Subtypes Vary With Indigenous Ancestry in Latin American Women Jan 31, 2020 Cytovia's CAR NK Alliance With NYSCF, UCSF Aims to Overcome Negative Side Effects of CAR T Drugs Premium May 31, 2019 Single-Cell Sequencing Proves Useful for Tracking Drug-Resistant AML Mutation Progression Premium May 29, 2019 CRISPR Framework Helps Identify Combination Therapies for Optimal Targeting of KRAS Mutant Oct 15, 2018 Liquid Biopsy Shows Promise for Monitoring Childhood Brain Tumors Jul 9, 2018 Melanoma Studies Reveal Mutations Contributing to Cancerous Transition Jun 26, 2018 Rare Immune Cells, Cytokine May Predict Response to Cancer Immunotherapy Nov 6, 2017 Multiple Genetic Alterations Uncovered in Advanced EGFR-Mutant Lung Cancer Patients Breaking News Flare Therapeutics Raises $123M in Oversubscribed Series B Funding Round William Blair Initiates Coverage of MDxHealth With Outperform Rating White House Report Outlines Goals to Advance Genomic Research, Precision Therapy Development In Brief This Week: Fore Biotherapeutics, RayzeBio, Gilead Sciences, Atossa Therapeutics Bayer to Assess Nubeqa in High-Risk, Early-Stage Hormone-Sensitive Prostate Cancer BridgeBio Begins Phase I/II Study of SHP2 Inhibitor, Opdivo in KRAS-Mutant Solid Tumors
